BenevolentAI
regulatory validation a covid treatment now fully approved for use by the novel our technology and work a previously unknown antiviral mechanism published research in rapid the benevolent platform empowered scientists to rapidly formulate a hypothesis in just hours effective shown to reduce mortality from covid in controlled trials barrier trial showed reduces mortality by in patients and by in ventilated or patients led to equity investment from approved the use of to treat covid in may after granting emergency use for in combination with in identified lancet | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
25 of 74
Similar slides by BenevolentAI
See diffirences between slides (animation)
Investor Conference
November 2022
regulatory validation a covid treatment now fully approved for use by the novel our technology and work a previously unknown antiviral mechanism published research in rapid the benevolent platform empowered scientists to rapidly formulate a hypothesis in just hours effective shown to reduce mortality from covid in controlled trials barrier trial showed reduces mortality by in patients and by in ventilated or patients led to equity investment from approved the use of to treat covid in may after granting emergency use for in combination with in identified lancet | BenevolentAI
Investor Presentation
October 2022
regulatory validation a covid treatment now fully approved for use by the novel our technology and work a previously unknown antiviral mechanism published research in rapid the benevolent platform empowered scientists to rapidly formulate a hypothesis in just hours effective shown to reduce mortality from covid in controlled trials barrier trial showed reduces mortality by in patients and by in ventilated or patients led to equity investment from approved the use of to treat covid in may after granting emergency use for in combination with in identified lancet | BenevolentAI
Related slides by other companies
Aeglea BioTherapeutics
Investor Presentation
August 2020
increased mortality and severe complication risk in patients with | Aeglea BioTherapeutics
Nuvalent
Investor Presentation
January 2024
coal execute on global first pivotal registrational data strategies first approved product mission bringing new potential best in class medicines to patients with cancer anticipated milestones progress phase with registrational intent initiate phase with registrational intent initiate phase trial for launch alk strategy and alk programs interim data for both her program i | Nuvalent
Nuvalent
Investor Presentation
January 2024
a rationally designed selective sparing inhibitor medical needs preliminary phase conclusions approved approved approved investigational by activity mutant activity activity key observed in clinical investigation activity observed in patients with including after exhausting approved and investigational therapies such as and activity observed in patients with resistance mutations activity mutant activity activity activity observed in patients with history of metastases including intracranial responses avoiding emerging safety profile was consistent with design with no dose reductions or treatment discontinuations due to adverse events source head to head clinical studies comparing with currently approved or investigational therapies have not been conducted | Nuvalent
Nuvalent
Investor Presentation
January 2024
coal execute on global first pivotal registrational data strategies first approved product mission bringing new potential best in class medicines to patients with cancer anticipated milestones progress phase with registrational intent initiate phase with registrational intent initiate phase trial for launch alk strategy and alk programs interim data for both her program i | Nuvalent
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io